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Purpose: To investigate whether tolerance to the anti-VEGF drug, ranibizumab, develops 
after drug exposure and to determine whether the history of treatment with ranibizumab prior 
to refractoriness can predict the post-switching responses to aflibercept.
Methods: We retrospectively investigated neovascular age-related macular degenera-
tion patients refractory to ranibizumab (intra- or subretinal fluid despite monthly injections 
for $6 months) who were switched to aflibercept and were followed up for at least 12 months 
on each of ranibizumab and aflibercept. Baseline characteristics and ranibizumab and aflibercept 
treatment history (number of injections during the first year and central retinal thickness [CRT]) 
were analyzed by univariate and multivariate correlation analyses.
Results: Ninety-eight eyes (88 patients, 70% females, mean age 77.5 years), including a high 
proportion of eyes with pigment epithelium detachment (63%), were treated with a mean of 
26.2 injections during 36.8 months before switching to aflibercept. The number of ranibizumab 
injections required in the first year (p=0.0002) and the presence of pigment epithelium detach-
ment (p=0.025) predicted the number of post-switching aflibercept injections required. The 
post-switching CRT change was predicted by the CRT increase from Month 3 to the switch 
time point (p,0.0001). Moreover, the CRT change correlated with the visual acuity benefit 
post-switching (p=0.038 and p=0.004, at 3 and 12 months post-switching, respectively).
Conclusion: Ranibizumab treatment history before switching to aflibercept correlates with the 
post-switching response in terms of the number of drug injections needed and CRT. Thus, drug 
tolerance does indeed exist and this might help to identify switching candidates.
Keywords: nAMD, ranibizumab, aflibercept, treatment history, switch-response, drug toler-
ance hypothesis
Introduction
The current standard of care for neovascular age-related macular degeneration (nAMD) 
involves repeated intravitreal injections of an anti-VEGF drug. Both ranibizumab1,2 
and aflibercept3 have shown good efficacy in the improvement of visual acuity in 
large multicenter randomized controlled Phase III trials. Both drugs showed equiva-
lent visual outcomes,3 despite different pharmacological profiles. Ranibizumab is a 
recombinant, humanized Fab fragment, with the Fc fragment removed from the parent 
molecule. In contrast, aflibercept is a soluble decoy receptor fusion protein (115 kDa) 
that involved fusing the second binding domain of the native VEGF receptor 1 and 
the third binding domain of VEGF receptor 2 to the Fc component of human IgG. 
Aflibercept is considered to have a much higher affinity for VEGF, based on in vitro 
measurements;4 however, more recent experiments challenge this perception, showing 
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equivalent VEGF inhibitory functions.5 This corresponds 
well with clinical observations of a comparable, although 
not identical, need for re-treatment with either drug (the pro 
re nata period in the VIEW study).6
In routine clinical care for nAMD, most ophthalmolo-
gists opt for a variable dosing regimen with anti-VEGF, 
based on clinical observation of disease activity recurrence 
as the indicator for re-treatment.7–9 This has been shown to 
be noninferior to a fixed monthly regimen and allows reduc-
tion of the number of injections without loss of efficacy.10–13 
However, the need for re-treatment is highly variable between 
patients,7,14–16 although it is relatively stable over time for a 
given patient.16 A proportion of patients require monthly 
re-treatment, but, even with maximal treatment at 1-month 
intervals, some eyes do not achieve an exudation-free status 
of the macula, at least not at the monthly follow-up time 
points.10,11 This can be observed immediately after initia-
tion of treatment in some cases, or only later in the time 
course after an initially satisfying response to treatment in 
other cases. Several authors have interpreted this secondary 
refractoriness as tachyphylaxis to the drug.17–20 For historical 
reasons, this has mainly been reported for ranibizumab and 
bevacizumab, as aflibercept became available only several 
years later and was often used when switching to a different 
anti-VEGF molecule.
However, the concept of tachyphylaxis has been con-
tested by some authors, because it suggests that efficacy can 
again be increased by increasing the treatment interval.21 
Indeed, resistance, tachyphylaxis, and drug tolerance are not 
identical.21,22 The term “resistance” is aimed at describing 
the status of a diminished therapeutic effect despite continu-
ous treatment, and in this case AMD itself is described as 
“refractory” or “recurrent”. The term “drug tolerance” is a 
pharmacology concept, where a subject’s reaction to a spe-
cific drug is reduced following repeated use, subsequently 
requiring an increased dosage or shorter dosing time inter-
vals to achieve the desired effect. However, efficacy is not 
restored even when the treatment is halted temporarily. The 
term “tachyphylaxis” is a medical term describing an acute 
decrease in the response to a drug after its administration. 
It cannot be overcome by increasing the dosage. However, 
efficacy can be restored if the medication is stopped for a 
short while or if the interval between doses is increased.23 The 
term drug tolerance is pharmacologically more appropriate 
for patients with a need for increased treatment over time. 
During anti-VEGF therapy, pharmacodynamic and pharma-
cokinetic tolerance may develop. The former can be caused 
by the increased expression of VEGF and VEGF receptors, 
changes in signal transduction, or a shift of the stimulus for 
choroidal neovascularization (CNV) growth toward other 
growth factors; the later occurs because a decreased quantity 
of the anti-VEGF reaches the site it affects (explained by the 
development of systemic immune response and neutralizing 
antibodies, increased clearance from the eye, or reflux of the 
drug following injection).23 To date, this issue has not been 
completely elucidated. However, many studies have observed 
improved structural outcome of refractory cases when chang-
ing to a different anti-VEGF drug, mostly from ranibizumab 
or bevacizumab to aflibercept,19,23–31 but recently also from 
aflibercept back to ranibizumab.32,33 Although these reports 
are difficult to interpret in the absence of appropriate control 
arms, authors have considered the effect of tachyphylaxis/
drug tolerance, as well as the differences between the drugs, 
or the natural course of time on treatment.24,34 The proposed 
mechanisms of improved efficacy after switching between 
two anti-VEGF drugs can be explained by different molecular 
sizes and the associated transport of molecules through the 
retina and into the subretinal space (ranibizumab compared 
to bevacizumab), higher binding efficacy, and a wider spec-
trum of action (aflibercept compared to both bevacizumab 
and ranibizumab).19,23–31
Thus, the aim of the present study was to investigate the 
relationship between ranibizumab treatment history before 
switching and the effect of a treatment switch to aflibercept in 
eyes with nAMD that are refractory to ranibizumab, in order 
to evaluate the evidence for the drug tolerance hypothesis.
Methods
This study was a retrospective file review that was performed 
at the Medical Retina Service of the Jules Gonin University 
Eye Hospital in Lausanne, Switzerland. The study was 
approved by the Swiss Federal Department of Health for 
retrospective data analysis and was performed in accordance 
with the ethical standards in the Declaration of Helsinki. The 
need for obtaining informed consent was waived due to the 
retrospective nature of the study. The patient data accessed 
were anonymous.
The institutional database was used to identify all 
consecutive patients with nAMD who had been switched 
from ranibizumab to aflibercept, after receiving monthly 
intravitreal injections during the 6 months preceding the 
switch. Additional inclusion criteria were that anti-VEGF 
treatment with ranibizumab had been initiated at least 
12 months before the switch and that the patients had been 
followed up for at least 12 months after the switch. The 
search was performed in December 2015 and included 
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patients with treatment initiation between March 2008 and 
December 2013. The identified patients’ files were then 
evaluated for the following more precise inclusion criteria. 
Despite monthly re-treatment before switch, the eyes had to 
have shown evidence of persistent (intra- or subretinal) fluid 
on spectral domain optical coherence tomography (SD-OCT) 
at all visits at 1-month intervals from the last injection for 
6 months or more, which prompted the decision to switch 
anti-VEGF drug. The investigated switch had to be the first 
anti-VEGF drug switch. The same type of SD-OCT device 
was used during the whole analysis period (until 12 months 
post-switch) (SD-OCT Cirrus [Carl Zeiss Meditec, Inc., 
Oberkochen, Germany] or Spectralis OCT [Heidelberg 
Engineering, Heidelberg, Germany]). Exclusion criteria were 
insufficient SD-OCT image quality or change in the SD-OCT 
device during the follow-up period, confounding retinal 
pathologies (including polypoidal choroidal vasculopathy), 
the use of any type of combination therapy (eg, anti-VEGF 
combined with photodynamic therapy), or interruption of the 
follow-up or treatment.
All patients initially received three loading doses of 
intravitreal ranibizumab injections (0.5 mg each). There-
after, the principle of treat and extend was applied, with a 
lengthening of the interval in the absence of disease activity 
and a shortening of the interval in cases of disease activity 
(minimum 1 month and maximum 3 months). The disease 
activity criteria involved the presence of intra- and/or sub-
retinal fluid on SD-OCT or new retinal hemorrhage. After 
switching to aflibercept, eyes were again treated with three 
monthly aflibercept intravitreal injections, and with a treat 
and extend regimen thereafter.
Baseline examination and all subsequent follow-up 
visits included best-corrected visual acuity (BCVA) on an 
Early Treatment of Diabetic Retinopathy (ETDRS) chart, 
a slit lamp examination, measurement of the intraocular 
pressure, a dilated fundus examination, and an OCT exami-
nation (128×512 cube examination on SD-OCT Cirrus or 
49 line cube examination on a Spectralis OCT). The same 
imaging device had to be used consecutively for the same 
patient at different time points. Fundus color photography, 
fundus autofluorescence imaging, fluorescein angiography, 
and indocyanine green angiography (TRC-501X; Topcon, 
Tokyo, Japan) were performed at baseline, at Month 3, and 
annually thereafter. Additional imaging was performed at 
the physician’s discretion.
Data on age, sex, angiographic lesion type, and the 
presence of pigment epithelium detachment (PED) were 
collected at baseline. Additional data on baseline and at 
different follow-up time points (Month 3 after baseline, 
the switch time point, and at Months 3 and 12 after switch-
ing) included BCVA, central macular thickness, and the 
presence or absence of intraretinal cysts or subretinal 
fluid. Furthermore, treatment data were collected for the 
number of injections during the first 12 months, the total 
number before the switch, and during the 12 months after 
the switch.
The primary outcome was the number of injections of 
anti-VEGF drug required after the switch. The secondary 
outcome was the central retinal thickness (CRT) change and 
BCVA change after switching drugs.
statistical analysis
For statistical analysis, we used descriptive statistics, Pearson’s 
correlation analysis, and analysis of variance (ANOVA) for 
continuous variables, and chi-square tests for categorical vari-
ables (presence or absence of disease activity). A multivariate 
linear regression analysis was performed to evaluate factors 
that retained a p-value ,0.2 in univariate analysis, in order 
to create a best-fitting model with the treatment history ele-
ments available and to determine the independent predictors 
of the response after switching. Statistical significance was 
set at p,0.05. For data analysis, a spreadsheet on Microsoft 
Excel 2010 and JMP software for Windows (version 8.0.1; 
SAS institute Inc., Cary, NC, USA) were used.
Results
During the defined study period, 98 eyes of 88 patients 
(62 females [70%], mean age 77.5±6.9 years) fulfilled 
the inclusion criteria. They were treated with a mean of 
26.2±12.0 injections during 36.8±18.9 months before switch-
ing to aflibercept.
At baseline, occult CNV was present in 58.2% of eyes, 
minimally classic CNV in 19.4% of eyes, predominantly 
classic CNV in 13.3% of eyes, and retinal angiomatous pro-
liferation in 9.2% of eyes. PED was seen in 63% of eyes.
BCVA was a mean of 65.7±12.9 ETDRS letters at base-
line, and improved to 72.1±10.7 letters at Month 3 after 
initiating treatment. At the switch time point, the BCVA 
was a mean of 71.9±14.3 letters and showed no significant 
changes at 3 and 12 months post-switching (71.7±14.0 letters 
and 70.8±14.8 letters, respectively).
On SD-OCT, the macula was found to be free of exuda-
tive activity at Month 3 in 48% of eyes. After switching drugs 
because of the presence of refractory fluid during follow-up, 
26% of eyes were again found to be dry at 3 months post-
switching. Although absolute CRT values are influenced 
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by the OCT device used (18 eyes [16 patients] were fol-
lowed on the Heidelberg Spectralis SD-OCT, while 80 eyes 
[72 patients] were followed on the Zeiss Cirrus SD-OCT), 
the relative evolution of these values on the same machine 
is representative. The mean baseline CRT of 345±107 µm 
improved to a mean of 293±98 µm at Month 3, and increased 
again until to 349±109 µm by the switch time point. 
At 3 months post-switching, the mean CRT was 307±83 µm 
and then slightly decreased again to 300±80 µm by 12 months 
post-switching.
The mean number of injections per eye before switching 
was 26.3±12.0 injections, and the mean duration of treatment 
before switching was 36.8±18.9 months. During the first year 
of treatment with ranibizumab, the mean number of injections 
was 9.2±2.8 (including three ranibizumab loading doses). 
After switching, which was motivated by a need for monthly 
re-treatment during the $6 months immediately prior to 
switching, the number of re-treatments with aflibercept again 
dropped to a mean of 10.9±1.4 injections (including three 
aflibercept loading doses) during a 12-month period.
The results of univariate and multivariate analyses, 
correlating the treatment history with the post-switching 
results, are summarized in Table 1. When comparing the 
treatment history (first year with ranibizumab and evolution 
until switching due to the presence of refractory fluid) with 
the post-switching treatment response and treatment require-
ment revealed the following univariate results. In terms of 
the number of injections during the year after switching to 
aflibercept, there was a positive correlation with the number 
of injections required during the initial year with ranibizumab 
treatment (R2=0.35, p=0.0004). However, the presence of 
PED at baseline or at the switch time point showed a signifi-
cant association with the number of injections required after 
switching (p=0.042 and 0.046, respectively). There was no 
correlation with age, sex, angiographic type of CNV, BCVA 
changes, CRT changes, dryness after ranibizumab loading 
dose, and duration of treatment before switching.
In multivariate analysis, the number of injections in 
the first year, the presence of PED, and sex were included 
(p,0.2). After stepwise multivariate linear regression, the 
final model was significant (R2=0.17, p=0.0001) and included 
the number of injections in the first year (estimated coefficient 
0.17±0.05, p=0.0002) and the presence of PED at baseline 
(estimated coefficient −0.30±0.13, p=0.025) as independent 
significant factors.
In terms of change in BCVA after switching (3 months 
after switching), there was no significant correlation found in 
the univariate analysis for the investigated treatment history 
factors. However, some factors with p,0.2 were included 
in the multivariate linear regression analysis: age, type of 
lesion, presence of PED, and BCVA change from Month 3 
to the switch time point. However, the final model was not 
significant ( p=0.07). Nevertheless, post-switching BCVA 
change was correlated with the post-switching CRT change, 
both at 3 months post-switching (R2=−0.21, p=0.038) and 
more markedly at 12 months post-switching (R2=−0.29, 
p=0.004).
In terms of CRT changes, there was a highly signifi-
cant correlation between CRT change from Month 3 (post 
loading phase of ranibizumab) to the switch time point and 
CRT change during the 3-month period after switching 
to aflibercept (R2=−0.47, p,0.0001). The more CRT had 
increased before switching, the more likely it was that the 
drug change would have a beneficial effect in decreasing CRT 
post-switching. In addition, there was a significant associa-
tion between the presence of PED at the switch time point 
and a more marked CRT decrease after switching (p=0.02). 
No other factor showed any association.
After multivariate analysis, the final model was sig-
nificant (p,0.0001), with an R2=0.26, and revealed that the 
change in CRT from Month 3 until the switch time point 
was the only independent significant predictor (estimated 
coefficient −0.23±0.05, p,0.0001) of the CRT change after 
switching, and that the presence of PED at the switch time 
point was not a completely independent factor (p=0.10).
Discussion
The aim of the present study was to investigate patients’ treat-
ment history for evidence of drug tolerance or tachyphylaxis 
hypothesis in anti-VEGF treatment for nAMD,17,18,23 and its 
correlation with the switching response. We found evidence 
that drug tolerance exists and that it plays a role in a subset 
of anti-VEGF-refractory nAMD patients, who benefit from a 
drug switch. We showed significant correlation between the 
early requirement for treatment and the treatment require-
ment after switching the anti-VEGF drug, as well as the CRT 
increase from Month 3 to the switch time point in patients 
who were switched from ranibizumab to aflibercept because 
of their refractoriness, despite monthly re-treatment. PED 
was also found to play a role in predicting the treatment 
need after switching, but no other factors in the treatment 
history of these refractory eyes were found to be predictive 
of the post-switch response. In particular, no reliable history 
factor could predict the visual acuity change after switch-
ing, although the visual acuity change before switching 
almost reached statistical significance. However, the visual 
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post-switch response was inversely correlated with the post-
switch CRT change.
Our model was based on the assumption that cases who 
develop anti-VEGF drug tolerance over time would show 
good initial results in terms of CRT, dryness, number of 
injections, and potentially in BCVA, but that these gains 
would diminish over time.17,18 If drug tolerance develops 
specifically to the injected anti-VEGF molecule and does 
not correspond to a simple upregulation of VEGF (or other 
proangiogenic mediators), then these eyes could be expected 
to benefit from switching to a different anti-VEGF molecule 
(from ranibizumab to aflibercept in this study). On the 
other hand, cases with a high treatment need and poor CRT 
response from the beginning of anti-VEGF treatment would 
be more likely to have inherently high VEGF production, or 
different mechanisms may be involved, and would not benefit 
as much from an anti-VEGF molecule switch. Visual acuity 
response is strongly influenced by multiple factors, such as 
fibrosis, atrophy, and hemorrhage, and was therefore a less 
plausible candidate than CRT and number of injections for 
evaluating our hypothesis.
Our findings were statistically significant and were con-
gruent with the drug tolerance hypothesis; however, this 
explanation is applicable for a subset of patients only. Our 
simple model of drug tolerance with a secondary appearing 
refractoriness versus inherent high treatment requirement in 
primary refractoriness does not explain the switch response in 
full. The multivariate model for predicting the post-switching 
treatment need had a goodness of fit R2 of 0.17, suggesting 
that not more than 17% of the variability in the treatment 
need is explained by the first year’s treatment need and the 
presence of PED. Similarly, the multivariate model for pre-
dicting post-switching CRT change had a goodness of fit R2 
of only 0.26 and included the presence of PED, which was 
not an independent, significant factor. Clearly, other factors 
are also implicated in the response to switching anti-VEGF 
from one molecule to another in refractory cases. Candi-
date factors are the normal time course of the disease, the 
regression to the mean, drug differences, and the hazard of 
more intensive treatment. Our study showed that a subset 
of eyes, which developed secondary refractoriness despite 
a good early treatment response, would respond well to a 
drug switch. This is different from eyes characterized by a 
CNV producing inherently high levels of VEGF, in which 
refractoriness was present from the beginning, and in which 
the response to switching was poorer (we term this “primary 
refractoriness”).
PED was also found to influence the response to switch-
ing. This factor was included in the analysis due to its 
high prevalence at baseline and at switching, and because 
previous publications had indicated that PED may play a 
particular role in the different responses to ranibizumab 
and aflibercept.24,35,36 Cases with PED often derived less 
benefit from switching, in terms of the number of injections 
needed during the year after switching, than those without 
PED. This finding was clearly independent and remained 
significant in the multivariate analysis. PED is indeed fre-
quently associated with a high treatment requirement, even 
if re-treatment is based on intra- or subretinal fluid rather 
than sub-pigment epithelium fluid.28,30 This component of 
the high treatment need associated with PED is present both 
before and after switching, and it is therefore not surprising 
that PED enhanced the post-switching treatment requirement. 
However, the role of PED in post-switching improvement 
in CRT was the opposite: PED cases showed more CRT 
changes after switching than did those without PED. This is 
not contradictory with the observation of less benefit from 
injections, because some of our patients (18%) were observed 
with the Heidelberg Spectralis SD-OCT, which includes PED 
into its CRT measurements, and because PED itself shows 
a greater height reduction in response to aflibercept than to 
ranibizumab.35,36 However, this complicates the interpreta-
tion of our findings.
Visual acuity has rarely been reported to benefit from 
anti-VEGF drug switching in uncontrolled reports;30,37 most 
studies did not show a significant change.24–27,29 Visual acuity 
is the result of multiple factors that influence the vitality and 
function of the retinal pigment epithelium and the photore-
ceptors, including the exudation observed as a marker of dis-
ease activity. Severe exudation has an immediate impact on 
visual acuity, and its medical control allows partial reversal of 
this, depending on the level of established damage. However, 
chronic low-degree exudation, as often seen in anti-VEGF-
treated nAMD with some remnant refractory fluid may be 
less directly linked to vision and may be less threatening in 
the short and median terms.38,39 However, the type of fluid 
appears to play a role, with subretinal fluid associated with 
better visual prognosis than intraretinal fluid.38,40–43 However, 
there is a tendency for cases with nAMD to lose vision over 
time, even with anti-VEGF treatment.44,45 Therefore, it still 
appears attractive to attempt to control the remnant refrac-
tory fluid, in the assumption that this will help to maintain 
vision in the long term. Thus, it is particularly interesting 
that we found a correlation between CRT change and BCVA 
change post-switching, which was statistically significant at 
both time points, that is, 3 months post-switching and even 
more markedly at 12 months post-switching. This may high-
light the importance of identifying the best candidates for 
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switching; the finding of a correlation with prior treatment 
history in this study may facilitate this.
Besides the inherent weaknesses of a retrospective study, 
the limitations of the present study include the inhomogeneity 
of the SD-OCT used for follow-up investigations. This 
particularly limits the interpretation of the PED effect. How-
ever, as each patient was followed individually on the same 
machine, the study still provided an important observation 
that previous CRT will be predictive of the CRT response 
to switching.
In conclusion, the present study revealed that the previous 
history of a refractory nAMD patient may inform clinicians 
about the likelihood of the response to a treatment switch 
from ranibizumab to aflibercept. Further studies are needed 
to confirm this finding, to identify the entire spectrum of 
influencing factors, and to investigate whether these factors 
are also applicable for switching eyes refractory to aflibercept 
to ranibizumab.
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